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Abstract We studied the deliverability and safety of a
braided, self-expanding, closed-cell nickel–titanium (NiTi)
stent (E-volution, Jotec GmbH, Hechingen, Germany)
especially designed for the endovascular treatment of car-
otid artery bifurcation stenosis with special regard to in-
stent stenosis and thrombosis compared with a laser-cut
reference nitinol stent in a porcine model of percutaneous
vascular interventions. We aimed to assess histopathologic
response in minipig carotid and subclavian arteries. Eight
minipigs received a total of 42 stents: 14 reference stents
and 28 E-volution stents. Eleven of the E-volution stents
were additionally coated with heparin. Control angiogra-
phy was obtained immediately before and after vascular
intervention as well as 4 weeks after the procedure.
Primary endpoints were 28 days of angiographic analyses
as well as histomorphometric analysis, including injury
score, inﬂammation score, luminal diameter, vessel
diameter, maximal neointimal thickness, and area of in-
stent stenosis. Secondary end points were procedural suc-
cess, 28-day mortality, and stent thrombosis. All stents
could be delivered successfully without procedural com-
plications, morbidity, or mortality during our observation
time. As conﬁrmed by histology, no in-stent thrombosis
was observed. Compared with common carotid arteries,
subclavian arteries are signiﬁcantly more vulnerable to
developing in-stent stenosis caused by neointima prolifer-
ation (p\0.05). Compared with the use of 1 single stent/
artery, serial application of two stents leads to a more
excessive but not signiﬁcantly different neointimal prolif-
eration (p[0.05). The E-volution stent, especially when
heparin coated, is in line with the comparison to the laser-
cut reference stent displaying similar results of angio-
graphic, histologic, and histomorphometric analyses
(p[0.05). Compared with the reference laser-cut stent,
the self-expanding nitinol stent (E-volution) with its
advanced braiding technology is feasible and safe. In our
opinion, the high radial resistive force and the advanced
braided design with tight stent-strut interstices may be
beneﬁcial in terms of plaque stabilization. Further studies
are necessary and warranted.
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Introduction
Carotid artery stenosis is a major cause of recurrent
ischemic stroke in patients with a history of recent transient
ischemic attacks or recent cerebral infarction. During
the past decade, the use of endoluminal self-expanding
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cutaneous carotid intervention, especially after clinical
trials showed evidence of decreased restenosis rates com-
pared with balloon angioplasty alone [1, 2]. In case of
symptomatic carotid artery stenosis, carotid artery stenting
(CAS) has shown its efﬁcacy, especially in patients with
high-risk factors for surgery, such as anatomically inac-
cessible lesions above the second cervical vertebra. Con-
tralateral occlusion of the internal carotid artery, restenosis
of previously operated bifurcation stenosis, radiation-
induced stenosis, recent myocardial infarction, and endo-
vascular treatment actually may be better treated by CAS
than by surgery [3–5].
Appropriate drug therapy with dual antiplatelet medi-
cation has already shown its impact in preventing throm-
bosis and early in-stent stenosis, which is of major concern
in terms of stent-related complications [6]. Another com-
plication is periprocedural embolization caused by
mechanical plaque destabilization during stent deployment.
Recent studies indicate the importance of the stent design,
suggesting that complication rates vary according to the
stent type, free cell area, and cell design. With only two
reports available, the level of evidence seems to be not very
high; however, the possibility that the complication rate
may be inﬂuenced by the stent design is an interesting
theory [7, 8]. Further investigations comparing stent devi-
ces may be warranted to analyze the impact of the stent
design. Technical innovations, especially regarding stent
design, may contribute to improve overall outcome in
patients after CAS. Because preclinical testing is essential
to investigate in vivo biocompatibility, inﬂammatory
response, and vessel injury related to a new device, the
purpose of our study was also to investigate the inﬂuence
of stent design on neointimal formation and thereby in-
stent stenosis. As a result, we conducted an experimental
study to compare neointimal formation and vascular
patency after implantation of the advanced braiding NiTi
stent and a laser-cut NiTi stent in a porcine model (Fig. 1).
Materials
All experiments were conducted in accordance with the
guidelines for animal experiments set forth by the Animal
Protection Committee of the local government. With the
subject under general anesthesia and using the open fem-
oral approach, 8 minipigs received a total of 42 stents.
These comprised 14 laser-cut NiTi stents (Precise RX,
Cordis, Miami, FL, USA) and 28 advanced braided NiTi
stents (E-volution, Jotec GmbH, Hechingen, Germany) in
the carotid and subclavian arteries bilaterally. To decrease
the number of the animals required for experimentation, 10
common carotid arteries were treated with 2 serial stents/
vessel, and 6 common carotid arteries received 1 single
stent (laser-cut or braided stent)/artery. Altogether, 9 laser-
cut stents, 8 braided stents without heparin coating, and 9
braided stents with additional heparin coating were
implanted in 16 common carotid arteries.
Two of 11 braided stents implanted in subclavian arteries
were also heparin coated. Five laser-cut nitinol stents were
implanted in subclavian arteries as reference. Figures 2A
and B provide examples of animal anatomy of common
carotid and subclavian arteries. Angiography was obtained
immediately before and after vascular intervention as well
as 4 weeks after stenting immediately before killing the
minipigs with a lethal dose of sodium pentobarbital.
Stent Systems
All stents were deliverable by 6F deployment systems,
which provide monorail technology. The deployment sys-
tems must be brought forth to target vessel position by way
of 6F shuttle select sheaths (Cook Medical, Bloomington,
IN) and 0.014-inch guidewires. According to minipig
vasculature, luminal diameter ranged from 4 to 6 mm
(Table 1). Vessel diameter was calculated by rule of pro-
portion using an intravascular reference (catheter tip with
known size), thus avoiding errors caused by plane of pro-
jection. The stent diameters chosen were approximately
10% to 15% larger than the lumen of the target artery
Fig. 1 A Reference testing stent with laser-cut technology (Precise
RX, Cordis, Miami, FL, USA). B Testing device E-volution carotid
stent with advanced braiding technology (E-volution, Jotec GmbH,
Hechingen, Germany)
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123position. All stents were 30 mm in their nominal implanted
length. Table 1 lists the features of the tested stents.
An outstanding characteristic of braided structures is the
constant luminal oriﬁce even when bent tightly back. The
ﬂexibility to tortuous vessels (Fig. 2C) is a further attribute
of the new stent. However, the vessel wall conformability
of some laser-cut stents is superior to classically braided
stents [9]. The invention of a new deployment system with
an integrated push–pull cinematic permits the precise
positioning and deployment of progressively braided
stents, such as the E-volution stent. This stent adapts per-
fectly to the typical anatomy of the carotid bifurcation with
its voluminous wide-meshed proximal part, which supports
the stent in the common carotid artery. It adapts with its
tightly braided distal section to the stenosis, which is typ-
ically located nearby the internal carotid artery bifurcation
[10]. The test device (Fig. 1B) represents over its whole
length of 30 mm the functional section of the basic con-
struction. Because the new stent has high vessel-surface
coverage, the arrangement of the wires may work as an
extraordinary tight mesh that stabilizes the plaque, thereby
preventing embolic complications. The relative stent-free
surface areas versus diameter expansion of laser-cut stents
(thin curve) and advanced braiding stents (thick curve) are
shown in Figure 3. The curves were calculated with
parameters that could be obtained through microscopic
planimetric measurements. For the Precise stent (Fig. 1A)
the absolute surface contact is always constant
(A = 63.6 mm
2). However, the relative surface contact
decreases if the stent diameter is expanded. As a result, the
stent-free area increases also with an increasing stent
diameter. The relative stent-free surface area of a braided
stent (Fig. 1B) ﬁrst increases until a local maximum has
been achieved depending on diameter and initial braiding
Fig. 2 Vascular anatomy of
minipigs. In 7 of 8 minipigs
treated, both CCAs derived
from a common trunk. A
Carotid bifurcation (arrow)i s
immediately below the skull
base. B Fluoroscopic
angiography 4 weeks after
stenting of the left subclavian
artery. C Flexibility of new
braided stent
Table 1 General characteristic features of the tested stents
Feature E-volution carotid stent (Jotec GmbH);
6F introducing sheath
Precise RX stent (Cordis);
6F introducing sheath
Implantation
a
Two serial stents (CCA) 1 stent (CCA) 7 9 2 stents (heparin coated n = 7) 3 9 2 stents/vessel
3 9 1 stent (heparin coated n = 2) 3 9 1 stent
1 stent (subclavian artery) 11 9 1 stent (heparin coated n = 2) 5 9 1 stent
Material NiTi alloy (50.6% Ni, 49.2% Ti, and 0.24% Cr) Nitinol (51.5% Ni and 48.5% Ti)
Design Braiding of 24 9 0.1 mm wires Laser-cut tubes; 0.1 mm wall thickness
Closed cell; ﬂared ends Open cell; cell size 5.89 mm
2; ﬂared ends
Surface Mechanically polished Electrolytically polished
Constrained lengths (mm) 65 to 106 (depending on braiding angle) 31.5
Unconstrained lengths (mm) 30 30
Unconstrained diameters (mm) 4, 5, and 6 5 and 6
Coating None (heparin coating n = 11): CCA (n = 9)
and subclavian artery (n = 2)
None
a n = 42 stents
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123angle, which can be expressed analytically. The absolute
and relative and stent-free area decreases if the braided
stent further expands (Table 1). The relative stent-free
surface can be calculated according to the following for-
mulas for two stents:
1. Precise stent (30 9 5 mm): A = superﬁcies surface of
stent: A = p 9 D 9 L, Where D is diameter, L is
length, and A (stent) = 63.6 mm
2. This is a constant
value of the Precise 30 9 5–mm stent. It was calcu-
lated by planimetric analysis, and calculation was done
by means of a measuring microscope. It is a
prerequisite for using the above-mentioned formula.
2. E-volution stent (30 9 5 mm): A (stent free)/A = (1 –
12 9 d /( p 9 D 9 sin a))
2.
For a given diameter D you can calculate the braiding
angle a with the second formula:
a ¼ arc cos D   cos a0=D0 ðÞ :
Parameters for the E-volution stent are as follows:
D0 ¼ 5mm, a0 ¼ 18 :
This means if
D= D 0 then
a = a0 and
d = 0.1 mm
The radial resistive force (RRF) can be obtained by
direct measurement caused by compression of a stent
between two ﬂat plates. The force curves represent the
stability of a stent against a potential radial force from
outside. The curves shown in Figure 4 were obtained from
a tightly braided NiTi and a laser-cut NiTi stent with same
relaxed diameters, lengths, and wall thicknesses. Figure 4
provides a qualitative impression of the potential of
braiding concerning RRF. Typical radial compression
hysteresis curves of RRF from laser-cut stents (lower
curve) and from advanced braided stents (upper curve) are
depicted in Figure 4.
Preparation and Histomorphometry
Aspirin (100 mg/d) and 75 mg clopidogrel were orally
administered starting 3 days before the procedure and
continuing until the minipigs were killed. After 28 days,
angiography was repeated. Immediately thereafter, the
animals were killed, the subclavian and carotid arteries
rapidly removed en bloc, the vessel system ﬂushed with
0.9% saline, and the arteries ﬁxed by means of perfusion
with 4% buffered formalin under physiologic pressure and
overnight immersion. The target segments were then dis-
sected, and samples were obtained for blinded histologic
evaluation. Stent-implanted arteries were immersed in
methylene methacrylate (Technovit 9100; Kulzer, Ger-
many). For all segments with stents, three trans-sectional
slices were prepared from the blocks with a coping saw,
polished, and glued on acrylic plastic slides for histomor-
phologic evaluation, with one at the entrance of the stent,
one in the middle of the stent, and one at the end of the
stent. Final specimens were stained using elastica van
Gieson and hematoxylin-eosin technique. After digitaliz-
ing, histomorphometric measurements were taken using the
National Institute of Health image program (Scion Image;
Scion, Frederick, MD). The parameters evaluated were
luminal diameter, external elastic lamina diameter (vessel
diameter), maximal neointimal thickness, external elastic
lamina area (vessel area), luminal area, neointimal area,
and area stenosis, which was determined as area steno-
sis = 100 – ([lumen area   100]/vessel area). An injury
score was assigned as previously described by Schwartz
et al. [11], and an inﬂammation score was determined
according to Kornowski et al. [12] by a reader with 5 years
of experience.
Statistical Analysis
Statistical difference between stent types, difference
between artery types, and inﬂuence of one versus two serial
stents were evaluated using nonparametric Kruskal–Wallis
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Fig. 3 Relative stent-free surface area versus diameter expansion of
laser-cut stents (thin curve) and advanced braiding stents (thick curve)
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Fig. 4 Typical hysteresis curves of RRF of laser-cut stents (lower
curve) and advanced braiding stents (upper curve). The stents are of
equal diameter, length, and of equal wall or wire thickness
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123test, which is a one-way analysis of variance by ranks. The
limit of statistical signiﬁcance was set at p\0.05; how-
ever, all p values should be interpreted in an explorative
fashion. SPSS software used for the evaluation (version
16.0; SPSS, Chicago, IL).
Results
Stent implantation was achieved without complication.
Angiography performed immediately after deployment
conﬁrmed full patency of all stents. After 28 days, all
vessels treated were angiographically patent as conﬁrmed
by histologic analysis. Microscopically, the stents appeared
to have been appropriately deployed, being closely opposed
to the media but not penetrating through it. Neointima in
carotid arteries was generally concentric. The periluminal
neointima contained multiple layers of circumferentially
oriented smooth muscle–like cells surrounded by extracel-
lular collagenous matrix without neovascularization.
The outer vessel diameter varied between 3 and 6.4 mm
(5 ± 0.07). Independent from stent design, neointimal
thickness of stents implanted in the subclavian arteries was
generally more distinctive than in carotid arteries. Regard-
ing the relative degree of in-stent stenosis, Figure 5 illus-
tratesthesigniﬁcantdifference(p\0.05)betweencommon
carotid and subclavian arteries and later showed a higher
rate of in-stent stenosis. Regarding inﬂammation and injury
scores, there were no signiﬁcant differences between the
different stent types. In carotid arteries, braided NiTi stents
showed a mean injury score of 0.7 ± 0.6 and an inﬂam-
mation score of 1.7 ± 0.9, which was comparable with
ﬁndings (injury score 0.3 ± 0.2; inﬂammation score:
1.9 ± 0.8) in slotted tube stents (Table 2). Mean neointimal
thickness of braided stents (0.51 ± 0.07 mm) was slightly
higher but not signiﬁcantly different compared with laser-
cut stents (0.47 ± 0.2 mm). Histomorphometric analysis of
the carotid arteries is listed in Table 2. Braided NiTi stents
have been shown to develop a thicker neointima; however,
no thrombosis or[60% in-stent-stenosis was observed. As
Figure 6 shows, the relative degree of in-stent stenosis in
carotid arteries did not show signiﬁcant differences
(p[0.05) between braided stents and slotted-tube NiTi
stents. Heparin coating of the braided stents yielded favor-
able results by decreasing in-stent stenosis; however, this
was statistically not signiﬁcant (Fig. 6). Carotid arteries
treated with only one stent showed lower in-stent stenosis
compared with the condition of two serial stents used per
treated artery (Fig. 7). However, this difference was not
statistically signiﬁcant (p[0.05) (Fig. 8).
Discussion
CAS is a rapidly evolving technique that has shown to be
technically feasible with an acceptable rate of complica-
tions [13–17]. Recently published guidelines from inter-
disciplinary consensus groups were deﬁned as demanding,
among others things, dedicated training of the interven-
tionalist, technical success rates [90%, and major com-
plication rates \5% in symptomatic and \7.5% in
asymptomatic patients with high risk for surgery [18–20].
In addition to guidelines to ascertain high-quality perfor-
mance of the procedure, advances in stent technology,
especially stent design, may contribute to decrease peri-
procedural complications.
The closed cell stent design covers a greater percentage
of the vascular wall in the stented region and thereby has
less uncovered cell area, which offers greater potential to
scaffold. This may support fractured plaque and stabilize
Fig. 5 Examples of transverse
histologic slices through arteries
treated with stents. A
Hematoxylin–eosin stain. B
Masson Goldner stain (original
magniﬁcation 920). Neointima
formation within the subclavian
arteries A was signiﬁcantly
more excessive (p\0.05) than
in common carotid arteries (B).
In the latter, stenosis was
typically concentric, whereas
more eccentric stenoses could
be observed in subclavian
arteries
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123material that could embolize to the brain. A recent study
regarding the use of a similarly tightly braided stent
(without additional coil embolization) for treatment of
aneurysms has shown its efﬁcacy to decrease intra-aneu-
rysmal perfusion [22]. Based on a retrospective analysis,
Bosiers et al. suggested that a smaller free-cell area asso-
ciated with closed-cell stents may prevent plaque emboli-
zation and therefore may decrease periprocedural and
postprocedural ischemic events [10]. Nevertheless, this
hypothesis has not yet been conﬁrmed by other randomized
trials [5]. A retrospective analysis of[700 carotid stenting
procedures showed only a trend (without statistic signiﬁ-
cance) toward lower event rates with closed-cell stents
[21]. Although clinical outcome after CAS is not inﬂu-
enced by only a single variable, the inﬂuence of stent
design that avoids, or at least decreases, risk of
periprocedural complications is not fully understood.
Because several animal studies exist regarding the use of
the Precise stent, we focused on the novel stent design,
which explains the higher number of vessels treated using
the novel stent [23, 24]. As Verheye observed in minipigs,
maximal intimal thickness in closed-cell laser-cut NiTi
stents depends on the anatomic vessel to be stented having
a mean diameter of 0.65 ± 0.13 mm described in the iliac
arteries and 0.55 ± 0.07 mm in the carotid arteries. In our
animal cohort, neointimal thickness within carotid and
subclavian arteries stented with the same type of United
States Food and Drug Administration–approved NiTi stents
was also different, suggesting that subclavian arteries are
more susceptible to developing in-stent stenosis. This has
Table 2 Histomorphometric ﬁndings in the carotid arteries
a
No. Descriptive
parameters
Vessel
diameter
(mm)
Luminal
diameter
(mm)
Maximum
neointimal
thickness
(mm)
Neointimal
area (mm
2)
Stenosis
(%)
Injury score
points (0 to 3)
Inﬂammation
score points
(0 to 3)
Precise stent
(n = 9)
Mean ± SD 5.5 ± 0.5 4.4 ± 0.4 0.5 ± 0.2 8.3 ± 2.1 34 ± 6.9 0.36 ± 0.2 1.7 ± 0.6
Maximum 6.4 5.2 0.8 6.0 49 1 3
Minimum 5.1 4.0 0.2 1.2 27 0 1.1
E-volution
stent
(n = 8)
Mean SD 4.4 ± 0.9 3.4 ± 0.9 0.5 ± 0.1 6.3 ± 1.4 40.1 ± 10.2 0.7 ± 0.7 1.6 ± 0.9
Maximum 5.1 4.3 0.5 8.4 56.1 2 3
Minimum 3.0 2.0 0.47 4.1 29.4 0 0.7
E-volution-Hep
stent
(n = 9)
Mean ± SD 4.7 ± 0.5 3.8 ± 0.5 0.5 ± 0.1 6.3 ± 1.1 35 ± 7.6 0.7 ± 0.6 1.8 ± 0.9
Maximum 5.6 4.7 0.6 7.6 52.3 2 3
Minimum 4.2 3.1 0.4 4.9 28.8 0 0.6
a Number of carotid stents results related to serial stentings (2 stents/vessel), which was performed in ﬁve of the eight animals. Statistical
analysis using nonparametric Kruskal–Wallis test, which is a one-way analysis of variance by ranks, showed no signiﬁcant difference (p\0.05)
Fig. 6 Relative degree of stenosis. Subclavian arteries showed
signiﬁcant (p\0.05) higher degree of in-stent stenoses compared
with carotid arteries
Fig. 7 Inﬂuence of stent design (Precise [n = 9], E-volution [n = 8],
E-volution [n = 9]). Heparin coating (E-volution-Hep stent) led to
decreased neointima formation of braided stents. However, there was
no statistically signiﬁcant difference between these three groups
(p[0.05)
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123also been reported for iliac arteries in minipigs [24] and
may be attributed to different physiologic strains in sub-
clavian compared with carotid arteries. This also may
explain the thicker neointima in Wallstents (Wallstent,
Boston Scientiﬁc Corp., Natick, MA, USA) implanted in
subclavian arteries compared with thinner neointimal pro-
liferation in iliac arteries of sheep [23].
High-pressure inﬂation with consequently higher injury
scores has been suggested as a cause of increased neoin-
tima formation [25]. Compared with other NiTi stents, one
advantage of this new stent is a high RRF. Because of its
braided design, radial forces are much higher than those of
laser-cut stents, which may supersede additional balloon
angioplasty to restore the stenosis after stent placement.
The lack of requirement for additional balloon angioplasty
may at least theoretically contribute to decrease vessel
damage. In addition, progressive intrinsic stent expansion
after implantation does not appear to stimulate neointimal
formation—at least not in the coronary circulation—and
therefore may provide a mechanical solution to decrease
neointima proliferation [25]. Despite the high amount of
metal in braided stents compared with laser-cut stents, the
range of injury scores and neointima formation we
observed was relatively low compared with other studies
[23, 24]. This might be explained by the high surface
coverage of braided stents, which generates only relatively
low penetrative force of each individual stent strut, thus
limiting the extent of vessel wall penetration and injury.
Given the great variety of different laser-cut stent design
available today, the braided Wallstent, which represents the
ﬁrst stent generation, seems to be a relic from the past.
However, in many cases it is best indicated for CAS
therapy because a huge percentage of experienced inter-
ventionalists use it, and its special features and mechanical
advantages, as compared with laser-cut stents, lend to its
widespread use. However, the Wallstent concept does not
exploit the full range of braiding options. Perhaps this is
related to conventional deployment techniques, which
demand no or faint foreshortening stent constructions. The
invention of a new deployment system with an integrated
push–pull cinematic permits the precise positioning and
deployment of progressively braided stents, such as the E-
volution stent.
In the case of placement of 2 serial stents/treated vessel,
which can be necessary because of stent malposition and
which is considered to be a risk factor for in-stent stenosis
[26], neointima thickness was slightly greater than in the
case of a single stent, which was observed not only for
slotted tubes but also for braided NiTi stents. In two carotid
arteries, an overlapping of strut elements was observed;
however, this did not produce in-stent thrombosis or stent
occlusion. This suggests the feasibility of the novel stent in
cases of malposition and the need for a second stent for
technical success. Compared with bare metal stents without
coating, heparin coating has been shown to be beneﬁcial in
decreasing neointimal formation and subsequent in-stent
restenosis, which has been reported previously for coronary
arteries [27, 28] and also for carotid arteries [28, 29].
This study has several limitations. Differences in the
structure and physiologic characteristics of carotid arteries
in minipigs compared with those in patients with athero-
sclerosis may have had an unpredictable inﬂuence. This
might also explain differences between the reaction of the
vessel wall in carotid compared with subclavian arteries.
There is no animal model of human carotid disease; there
are only animal models of how devices will behave in well-
characterized animal models [30–32]. True efﬁcacy and
safety can only be proven in humans. However, the minipig
model is considered to be a suitable model for preclinical
testing of the in-stent stenosis [24, 33].
Another limitation results from the short observation
period of only 4 weeks. This covers the most critical time
with respect to thrombotic events and healing. However, it
remains to be determined how observations will be made in
animals and especially in human patients. In addition, it
must be pointed out that regardless of the animal model
used, the transfer of results to humans is generally limited
but must be undertaken before its application in humans
[34].
Conclusion
Compared with the reference laser-cut stent, the novel
braided nitinol stent device for treatment of carotid artery
stenosis has two innovative characteristics: a three-fold
greater RRF as well as a high surface coverage. The self-
Fig. 8 Inﬂuence of two serial stents on in-stent stenosis caused by
intimal proliferation. Compared with only 1 stent/vessel treated, two
serial stents increased the danger of neointima formation. This
difference was not statistically signiﬁcant (p\0.05)
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123expanding nitinol stent (E-volution), with its advanced
braiding technology, is feasible and safe. However,
because preclinical studies are necessary to assure the
safety of the device, especially concerning neointima for-
mation and in-stent stenosis, animal studies must precede
its application for human carotid stenosis.
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